Crosstalk between the vitamin D receptor (VDR) and miR-214 in regulating SuFu, a hedgehog pathway inhibitor in breast cancer cells.
The vitamin D receptor (VDR), and its ligand 1α,25-dihydroxyvitamin D3(1,25D3) prevent breast cancer development and progression, yet the molecular mechanisms governing this are unclear. MicroRNAs (miRNAs) on the other hand, promote or inhibit breast cancer growth. To understand how VDR regulates miRNAs, we compared miRNA expression of wild-type (WT) and VDR knockout (VDRKO) breast cancer cells by a Mouse Breast Cancer miRNA PCR array. Compared to VDR WT cells, expressions of miR-214, miR-199a-3p and miR-199a-5p of the miR-199a/miR-214 cluster were 42, 15, and 10 fold higher in VDRKO cells respectively. Overexpression of VDR in breast cancer cells reduced the miR-199a/miR-214 cluster expression by 30%. VDR status also negatively correlated with Dnm3os expression, a non-coding RNA transcript of the dynamin-3 gene encoding the miR-199a/miR-214 cluster, suggesting that VDR represses this cluster through Dnm3os. Conversely, overexpression of miR-214 in MCF-7 and T47D cells antagonized VDR mediated signaling. Furthermore, there was a positive correlation between VDR status and the expression of Suppressor of fused gene (SuFu), a hedgehog pathway inhibitor. miR-214 on the other hand suppressed SuFu protein expression. These findings suggest a crosstalk between VDR and miR-214 in regulating hedgehog signaling in breast cancer cells, providing new therapies for breast cancer.
Cancer Biology Division, IIT Research Institute, Chicago, IL 60616, USA.
Fatouma
F
Alimirah
Cancer Biology Division, IIT Research Institute, Chicago, IL 60616, USA.
Xinjian
X
Peng
Cancer Biology Division, IIT Research Institute, Chicago, IL 60616, USA.
Akash
A
Gupta
Cancer Biology Division, IIT Research Institute, Chicago, IL 60616, USA.
Liang
L
Yuan
University at Albany Cancer Research Center, Rensselaer, NY 12144, USA.
JoEllen
J
Welsh
Merck Research Laboratories, Merck & Co., Inc., West Point, PA 19486, USA.
Michele
M
Cleary
Cancer Biology Division, IIT Research Institute, Chicago, IL 60616, USA. Electronic address: rmehta@iitri.org.
Rajendra G
RG
Mehta
D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D053823:Hedgehog Proteins / Q000378:metabolism*; D006801:Humans; D061986:MCF-7 Cells; D051379:Mice; D035683:MicroRNAs / Q000378:metabolism*; D018167:Receptors, Calcitriol / Q000378:metabolism*; D012097:Repressor Proteins / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D014807:Vitamin D / Q000031:analogs & derivatives / Q000494:pharmacology
D053823:Hedgehog Proteins; C547397:MIRN214 microRNA, human; D035683:MicroRNAs; C534781:Mirn214 microRNA, mouse; D018167:Receptors, Calcitriol; D012097:Repressor Proteins; C490764:SUFU protein, human; C118756:dihydroxy-vitamin D3; D014807:Vitamin D
Breast cancer; Crosstalk; Hedgehog signaling; MiR-214; Transrepression; Vitamin D receptor (VDR)